Bandaríkin - enska - NLM (National Library of Medicine)

meda pharmaceuticals - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - cholecalciferol 400 [iu]

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - cholecalciferol - bait - cholecalciferol vitamin-d3 active 0.75 g/kg - vertebrate poison

Nýja-Sjáland - enska - Ministry for Primary Industries

aotea ip holdings limited - cholecalciferol - cholecalciferol 8.07 g/kg - vertebrate toxic agent

Nýja-Sjáland - enska - Ministry for Primary Industries

animal control products limited trading as orillion - cholecalciferol - cholecalciferol 8 g/kg - vertebrate toxic agent

Nýja-Sjáland - enska - Ministry for Primary Industries

aotea ip holdings limited - cholecalciferol - cholecalciferol 4 g/kg - vertebrate toxic agent

Bandaríkin - enska - NLM (National Library of Medicine)

trigen laboratories, llc - levomefolic acid (unii: 8s95dh25xc) (levomefolic acid - unii:8s95dh25xc), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: 6so6u - levomefolate calcium 600 ug - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients including soy or fish oil.

Bandaríkin - enska - NLM (National Library of Medicine)

womens choice pharmaceuticals llc - thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium formate (unii: np3jd65npy) (calcium cation - unii:2m83c4r6zb), calcium carbonate (unii: h - ascorbic acid 120 mg - i ndications and usage: nestabs dha is indicated to provide vitamin/mineral and omega-3 fatty acid supplementation to women throughout pregnancy, during the postnatal for both lactating and nonlactating mothers. nestabs dha is also beneficial in improving the nutritional status of women prior to conception. c ontraindications:   this product is contraindicated in patients with a known hypersensitivity to any of the ingredients .

Bandaríkin - enska - NLM (National Library of Medicine)

method pharmaceuticals, llc - levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc) - levomefolate calcium 600 ug

Bandaríkin - enska - NLM (National Library of Medicine)

sterling knight pharmaceuticals,llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - cholecalciferol 5750 [iu] - revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, vitamin d deficiency or are in need of vitamin d supplementation and other nutritional supplementation. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients. revesta is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

Bandaríkin - enska - NLM (National Library of Medicine)

adler-stern pharmaceuticals, llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - cholecalciferol 3775 [iu] - ciferex is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, vitamin d deficiency or are in need of vitamin d supplementation and other nutritional supplementation. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients. ciferex is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.